Global Hepatitis A Vaccine 麻豆原创 Growth 2025-2031

Publication ID:

LPI03254882

Publication Date:

March 25, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Hepatitis A Vaccine market size is predicted to grow from US$ 749 million in 2025 to US$ 860 million in 2031; it is expected to grow at a CAGR of 2.3% from 2025 to 2031.
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml). 2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
The Hepatitis A vaccine market is primarily driven by the increasing awareness of hepatitis prevention, coupled with growing vaccination programs initiated by governments and health organizations globally. As hepatitis A is a highly contagious liver infection, the rising incidence of outbreaks, especially in developing regions, is pushing demand for vaccines. Moreover, the expanding travel industry, where travelers are required to be vaccinated for hepatitis A when visiting certain high-risk regions, is further bolstering market growth. In addition, advancements in vaccine technology and the increasing availability of combination vaccines are also contributing factors. However, the market faces several challenges. One of the primary challenges is the high cost of vaccines, especially in low-income regions, limiting access for vulnerable populations. Additionally, the lack of infrastructure and healthcare facilities in remote areas poses a significant barrier to widespread vaccine distribution. In certain regions, vaccine hesitancy due to misinformation and fear of side effects also hampers market growth, making public health education and outreach essential to overcoming these obstacles.
Global hepatitis a vaccine key players include GSK, Merck, Sanofi, etc. Global top 5 manufacturers hold a share over 80%. Asia-Pacific is the largest market, with a share over 38%, followed by North America and Europe , both have a share over 54%. In terms of product, inactivated vaccine is the largest segment, with a share about 85%. And in terms of application, the largest application is government institution, followed by private sector, etc.
The 鈥淗epatitis A Vaccine Industry Forecast鈥� looks at past sales and reviews total world Hepatitis A Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Hepatitis A Vaccine sales for 2025 through 2031. With Hepatitis A Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis A Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Hepatitis A Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis A Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Hepatitis A Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis A Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis A Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis A Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Inactivated Vaccine
Live Attenuated Vaccine
Segmentation by Application:
Government Institution
Private Sector
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
Merck
Sanofi
Sinovac
Zhejiang Pukang
Changchun Institute of Biological
KM Biologics
IMBCAMS
Convac
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hepatitis A Vaccine market?
What factors are driving Hepatitis A Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hepatitis A Vaccine market opportunities vary by end market size?
How does Hepatitis A Vaccine break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Hepatitis A Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Hepatitis A Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Hepatitis A Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Hepatitis A Vaccine Segment by Type
2.2.1 Inactivated Vaccine
2.2.2 Live Attenuated Vaccine
2.3 Hepatitis A Vaccine Sales by Type
2.3.1 Global Hepatitis A Vaccine Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Hepatitis A Vaccine Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Hepatitis A Vaccine Sale Price by Type (2020-2025)
2.4 Hepatitis A Vaccine Segment by Application
2.4.1 Government Institution
2.4.2 Private Sector
2.4.3 Other
2.5 Hepatitis A Vaccine Sales by Application
2.5.1 Global Hepatitis A Vaccine Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Hepatitis A Vaccine Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Hepatitis A Vaccine Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Hepatitis A Vaccine Breakdown Data by Company
3.1.1 Global Hepatitis A Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Hepatitis A Vaccine Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Hepatitis A Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Hepatitis A Vaccine Revenue by Company (2020-2025)
3.2.2 Global Hepatitis A Vaccine Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Hepatitis A Vaccine Sale Price by Company
3.4 Key Manufacturers Hepatitis A Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatitis A Vaccine Product Location Distribution
3.4.2 Players Hepatitis A Vaccine Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Hepatitis A Vaccine by Geographic Region
4.1 World Historic Hepatitis A Vaccine 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Hepatitis A Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Hepatitis A Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Hepatitis A Vaccine 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Hepatitis A Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Hepatitis A Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Hepatitis A Vaccine Sales Growth
4.4 APAC Hepatitis A Vaccine Sales Growth
4.5 Europe Hepatitis A Vaccine Sales Growth
4.6 Middle East & Africa Hepatitis A Vaccine Sales Growth
5 Americas
5.1 Americas Hepatitis A Vaccine Sales by Country
5.1.1 Americas Hepatitis A Vaccine Sales by Country (2020-2025)
5.1.2 Americas Hepatitis A Vaccine Revenue by Country (2020-2025)
5.2 Americas Hepatitis A Vaccine Sales by Type (2020-2025)
5.3 Americas Hepatitis A Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatitis A Vaccine Sales by Region
6.1.1 APAC Hepatitis A Vaccine Sales by Region (2020-2025)
6.1.2 APAC Hepatitis A Vaccine Revenue by Region (2020-2025)
6.2 APAC Hepatitis A Vaccine Sales by Type (2020-2025)
6.3 APAC Hepatitis A Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hepatitis A Vaccine by Country
7.1.1 Europe Hepatitis A Vaccine Sales by Country (2020-2025)
7.1.2 Europe Hepatitis A Vaccine Revenue by Country (2020-2025)
7.2 Europe Hepatitis A Vaccine Sales by Type (2020-2025)
7.3 Europe Hepatitis A Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hepatitis A Vaccine by Country
8.1.1 Middle East & Africa Hepatitis A Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Hepatitis A Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Hepatitis A Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Hepatitis A Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatitis A Vaccine
10.3 Manufacturing Process Analysis of Hepatitis A Vaccine
10.4 Industry Chain Structure of Hepatitis A Vaccine
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatitis A Vaccine Distributors
11.3 Hepatitis A Vaccine Customer
12 World Forecast Review for Hepatitis A Vaccine by Geographic Region
12.1 Global Hepatitis A Vaccine 麻豆原创 Size Forecast by Region
12.1.1 Global Hepatitis A Vaccine Forecast by Region (2026-2031)
12.1.2 Global Hepatitis A Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Hepatitis A Vaccine Forecast by Type (2026-2031)
12.7 Global Hepatitis A Vaccine Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Hepatitis A Vaccine Product Portfolios and Specifications
13.1.3 GSK Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Hepatitis A Vaccine Product Portfolios and Specifications
13.2.3 Merck Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Hepatitis A Vaccine Product Portfolios and Specifications
13.3.3 Sanofi Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Sinovac
13.4.1 Sinovac Company Information
13.4.2 Sinovac Hepatitis A Vaccine Product Portfolios and Specifications
13.4.3 Sinovac Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sinovac Main Business Overview
13.4.5 Sinovac Latest Developments
13.5 Zhejiang Pukang
13.5.1 Zhejiang Pukang Company Information
13.5.2 Zhejiang Pukang Hepatitis A Vaccine Product Portfolios and Specifications
13.5.3 Zhejiang Pukang Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Zhejiang Pukang Main Business Overview
13.5.5 Zhejiang Pukang Latest Developments
13.6 Changchun Institute of Biological
13.6.1 Changchun Institute of Biological Company Information
13.6.2 Changchun Institute of Biological Hepatitis A Vaccine Product Portfolios and Specifications
13.6.3 Changchun Institute of Biological Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Changchun Institute of Biological Main Business Overview
13.6.5 Changchun Institute of Biological Latest Developments
13.7 KM Biologics
13.7.1 KM Biologics Company Information
13.7.2 KM Biologics Hepatitis A Vaccine Product Portfolios and Specifications
13.7.3 KM Biologics Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 KM Biologics Main Business Overview
13.7.5 KM Biologics Latest Developments
13.8 IMBCAMS
13.8.1 IMBCAMS Company Information
13.8.2 IMBCAMS Hepatitis A Vaccine Product Portfolios and Specifications
13.8.3 IMBCAMS Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 IMBCAMS Main Business Overview
13.8.5 IMBCAMS Latest Developments
13.9 Convac
13.9.1 Convac Company Information
13.9.2 Convac Hepatitis A Vaccine Product Portfolios and Specifications
13.9.3 Convac Hepatitis A Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Convac Main Business Overview
13.9.5 Convac Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.